Biomaster, Inc.

Biomaster, Inc. (株式会社バイオマスター) is a Japanese research-and-development company dedicated to regenerative medicine, headquartered in Naka-ku, Yokohama, Kanagawa. It was established on 25 December 2002 with the stated aim of contributing to the development of the medical industry through innovative regenerative-medicine technologies. Since 2011 it has been a group company of Kaneka Corporation, which has supported the further evolution of its technology. The company describes itself as a venture engaged in cell research and treatment, and its mission is to make regenerative medicine more accessible. Its business spans three main pillars: a cell-processing contract service, in which medical institutions collect and send adipose tissue and Biomaster cultures adipose-derived stem cells for return to the clinic; sales of the Kaneka cell concentration and washing system, an automated device that concentrates and washes cell suspensions and, with dedicated accessories, isolates the stromal vascular fraction (SVF) containing adipose-derived stem cells from fat tissue; and application-document preparation support that helps medical institutions introduce regenerative medicine and handle regulatory filings. Biomaster also operates Cellport Clinic Yokohama (セルポートクリニック横浜), a medical institution opened in 2006 under the Structural Reform Special Zone Law (構造改革特別区域法), which permits a stock company to establish a medical institution within a designated special zone. The clinic operates in the KANAGAWA Bio Medical Industry Special Zone, the first medical special zone in Japan, approved by the national government in July 2005 after discussions between Kanagawa Prefecture and the company. At the clinic, Biomaster applies its own technology as CAL tissue augmentation therapy (CAL組織増大術), a treatment in which a patient's own aspirated adipose tissue is enriched with adipose-derived stem cells and injected. The clinic has provided regenerative medicine as a plastic and aesthetic surgery practice since opening in 2006, focusing on reconstructive treatments such as breast reconstruction after breast-cancer surgery and facial degenerative disease reconstruction, as well as aesthetic treatments such as breast augmentation and aging care. Biomaster positions itself as a bridge between its clinical experience and the wider medical community: it states that it has used its own developed cells in treatment for more than 15 years through Cellport Clinic Yokohama, and that its mission is to deliver the cell-processing technology and medical expertise built together with patients and clinical staff to patients and medical institutions that need them. The company's corporate message emphasizes supporting people who want to live their own lives by their own strength, trusting in the infinite power of cells, and it aims to help realize a life design in which people stay healthy and true to themselves until the end of their natural lifespan. It continues to exhibit at and co-host events such as the Japanese Orthopaedic Association academic congress and the Japanese Society for Regenerative Medicine annual meeting.

Biomaster, Inc. was established on 25 December 2002 as a research-and-development company founded to develop regenerative-medicine technologies. From its founding, the company aimed to contribute to the development of the medical industry through innovative regenerative-medicine technologies. A defining early challenge was the regulatory framework for regenerative medicine in Japan. Under the Structural Reform Special Zone Law (構造改革特別区域法), enacted in 2003, Article 18 permits a stock company to obtain approval to establish a medical institution within a structural reform special zone designated by a local government, for advanced medical care certified by the national government. Biomaster engaged with Kanagawa Prefecture from 2005, and in July of that year the national government approved the KANAGAWA Bio Medical Industry Special Zone (かながわバイオ医療産業特区), making Yokohama City in Kanagawa Prefecture a special zone where a stock company could open a medical institution. This was realized as Japan's first medical special zone, with support from Kanagawa Prefecture and related organizations. In 2006, Biomaster opened Cellport Clinic Yokohama as a company-operated medical institution under Article 18 of the law. Since opening in 2006, Cellport Clinic Yokohama has operated as a plastic and aesthetic surgery clinic providing regenerative medicine to many patients. It applies Biomaster's own technology as CAL tissue augmentation therapy, in which a patient's aspirated adipose tissue is combined with adipose-derived stem cells and injected. The clinic primarily performs reconstructive treatments such as breast reconstruction after breast-cancer surgery and facial degenerative disease reconstruction, as well as aesthetic treatments such as breast augmentation and aging care. In 2011, Biomaster became a group company of Kaneka Corporation. Under the Kaneka Group, the company has continued to advance its technology. Its cell culture work uses a high-proliferation culture method developed by Kaneka, performed by dedicated technicians. The company's regenerative-medicine solutions business has grown to include a cell-processing contract service, sales of the Kaneka cell concentration and washing system, and support for preparing regenerative-medicine application documents. The Kaneka cell concentration and washing system automatically concentrates and washes cell suspensions and, with dedicated accessories, can isolate the stromal vascular fraction (SVF) containing adipose-derived stem cells from fat tissue. By its own account, Biomaster has used its own developed cells in treatment for more than 15 years through Cellport Clinic Yokohama. The company continues to present its work in professional forums, including co-hosting a luncheon seminar and exhibiting a corporate booth at the 99th Japanese Orthopaedic Association Academic Congress and exhibiting at the 25th Annual Meeting of the Japanese Society for Regenerative Medicine. Its stated mission remains to deliver the cell-processing technology and medical expertise built together with patients and clinical staff to patients and medical institutions that need them, and to help realize a life design in which people stay healthy and true to themselves until the end of their natural lifespan.

• Biomaster, Inc. established as a research-and-development company for regenerative medicine.

• The Structural Reform Special Zone Law, which allows stock companies to open medical institutions in designated zones, is enacted.

• The KANAGAWA Bio Medical Industry Special Zone is approved by the national government, enabling a stock company to open a medical institution in Yokohama.

• Cellport Clinic Yokohama opens under Article 18 of the Structural Reform Special Zone Law.

• Biomaster becomes a group company of Kaneka Corporation.

• Exhibits at the 25th Annual Meeting of the Japanese Society for Regenerative Medicine.

• Co-hosts a luncheon seminar and exhibits a corporate booth at the 99th Japanese Orthopaedic Association Academic Congress.

A research-and-development regenerative-medicine company and Kaneka Group member that bridges clinical practice and medical institutions, offering cell processing, devices, and regulatory support.

• Cell-processing contract service

  Medical institutions collect and send adipose tissue; Biomaster cultures adipose-derived stem cells using Kaneka's high-proliferation culture method and returns them for treatment.

• Kaneka cell concentration and washing system

  An automated system that concentrates and washes cell suspensions; with dedicated accessories it can isolate SVF containing adipose-derived stem cells from fat tissue.

• Regenerative medicine application document preparation support

  Support for medical institutions considering regenerative medicine, covering application procedures and technology introduction.

• CAL tissue augmentation therapy

  A treatment provided at Cellport Clinic Yokohama in which a patient's aspirated adipose tissue is enriched with adipose-derived stem cells and injected.

1. 1株式会社バイオマスター｜再生医療で美容・健康・福祉へ貢献する研究開発型企業biomaster.jp
2. 2企業情報｜再生医療で人々に貢献する株式会社バイオマスターbiomaster.jp
3. 3Biomaster, Inc. (Japan) - Wikidatawikidata.org